Rochester, MN - A new case series of patients with a previous stroke suggests that transcatheter device closure of patent foramen ovale (PFO) and atrial septal defect (ASD) is safe and eliminated ...

The US Food and Drug Administration (FDA) has approved the Gore Cardioform septal occluder for closure of patent foramen ovale (PFO) to prevent recurrent ischemic stroke, the manufacturer, WL Gore & ...

FLAGSTAFF, Ariz. Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen ovale (PFO) can prevent recurrent ischemic strokes, W. L. Gore & Associates, Inc.

FLAGSTAFF, Ariz., March 11, 2021 /CNW/ -- W. L. Gore & Associates (Gore), today announced that Gore REDUCE Study long-term follow-up results were published in the March 2021 issue of The New England ...

Because the benefits of patent foramen ovale closure were once in question, physicians remain hesitant about its use in clinical practice. Recent data, however, have confirmed the safety and efficacy ...

Please provide your email address to receive an email when new articles are posted on . New data from the CLOSE, REDUCE and RESPECT trials demonstrated a lower rate of recurrent ischemic stroke after ...

Three months of clopidogrel is sufficient to curb new-onset migraine headaches after percutaneous atrial septal defect (ASD) closure, new data from the randomized CANOA trial show. There was no ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Atrial septal aneurysm (ASA) is defined as excursion of the atrial septum exceeding 10 mm beyond the ...

W.L. Gore & Associates (Gore) has launched a multicenter, prospective, randomized placebo- and sham-controlled investigational study that will evaluate the safety and efficacy of transcatheter closure ...

Percutaneous closure of patent foramen ovale (PFO) is a widely used procedure, but the long-term safety and efficacy of the technique have not been investigated. This prospective, observational, ...